Jeon Jae Yoon, Sparreboom Alex, Baker Sharyn D
Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy and Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA.
Clin Pharmacol Ther. 2017 Nov;102(5):726-730. doi: 10.1002/cpt.815.
Tremendous progress has been made by utilizing kinase inhibitors in oncology, and these agents continue to pave the way into other areas of medicine. There are, however, many challenges to the application of kinase inhibitors due to inherent shortcomings of the drugs and lack of comprehensive understanding of tumor and disease biology. The future fate of kinase inhibitors, however, is bright, as evidenced from ongoing efforts to increase their efficacy while remediating their weaknesses in order to provide the best quality of care to patients.
在肿瘤学领域，激酶抑制剂的应用已取得了巨大进展，并且这些药物继续为进入医学的其他领域铺平道路。然而，由于药物固有的缺点以及对肿瘤和疾病生物学缺乏全面了解，激酶抑制剂的应用面临许多挑战。然而，激酶抑制剂的未来前景光明，目前正在努力提高其疗效并弥补其弱点，以便为患者提供最佳的医疗服务，这一点就证明了这一点。
